Overview

Contrast-Enhanced Ultrasound Identification of Sentinel Nodes in Esophageal Cancer

Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This pilot trial studies how well an ultrasound with a contrast agent (perflubutane microbubble [Sonazoid]) works in identifying sentinel lymph nodes in participants with esophageal cancer. Sentinel lymph nodes are lymph nodes to which the cancer is likely to spread from the primary tumor. Diagnostic procedures, such as contrast-enhanced ultrasound, may work better in identifying sentinel lymph nodes and finding out how far the disease has spread.
Phase:
Early Phase 1
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University
Collaborator:
National Cancer Institute (NCI)